DC
ESPR

Diametric Capital’s Esperion Therapeutics ESPR Stock Holding History

Diametric Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-102,955
Closed -$282K – 539
2026
Q1 		$282K Sell
102,955
-66,051
-39% -$209K 0.07% 343
2025
Q4 		$625K Sell
169,006
-67,139
-28% -$217K 0.17% 170
2025
Q3 		$626K Sell
236,145
-442,679
-65% -$856K 0.23% 108
2025
Q2 		$668K Buy
678,824
+248,648
+58% +$249K 0.36% 82
2025
Q1 		$619K Buy
430,176
+76,166
+22% +$140K 0.74% 32
2024
Q4 		$779K Sell
354,010
-312,829
-47% -$730K 0.53% 54
2024
Q3 		$1.1M Sell
666,839
-77,003
-10% -$155K 0.54% 39
2024
Q2 		$1.65M Buy
743,842
+667,058
+869% +$1.57M 0.9% 18
2024
Q1 		$206K Sell
76,784
-11,386
-13% -$27.7K 0.11% 259
2023
Q4 		$264K Buy
+88,170
New +$114K 0.16% 174
2021
Q2 		– Sell
-8,902
Closed -$250K – 153
2021
Q1 		$250K Buy
+8,902
New +$263K 0.19% 106

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Diametric Capital's ESPR Position: Q2 2026 in Review

Diametric Capital sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 102,955 shares — an estimated $282K sold.

Diametric Capital first reported a position in ESPR in Q1 2021 and held it in 11 quarters. The position peaked at $1.65M in Q2 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Diametric Capital reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 102,955 Esperion Therapeutics shares in Q2 2026, an estimated $282K.
  • Diametric Capital first reported a position in Esperion Therapeutics in Q1 2021 and held it in 11 quarters.
  • Diametric Capital's Esperion Therapeutics position peaked at $1.65M in Q2 2024.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.